[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-001", "question": "A 34-year-old woman presents with 6 months of progressive bilateral hand weakness and numbness. She has a 15-year history of systemic lupus erythematosus treated with hydroxychloroquine and low-dose prednisone. Examination reveals symmetric weakness of finger abduction and adduction bilaterally, decreased sensation to pinprick over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies show reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. Anti-ganglioside antibodies are negative. CSF shows protein 85 mg/dL with 2 WBCs. Which of the following is the most likely diagnosis?", "options": ["Multifocal motor neuropathy with conduction block", "Chronic inflammatory demyelinating polyneuropathy", "Lupus-associated mononeuritis multiplex", "Lewis-Sumner syndrome", "Hereditary neuropathy with liability to pressure palsies"], "answer": "D", "answer_index": 3, "explanation": "Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is characterized by asymmetric sensorimotor involvement with demyelinating features including conduction block, distinguishing it from multifocal motor neuropathy (purely motor, anti-GM1 positive) and CIDP (symmetric). The presence of sensory symptoms and signs excludes MMN. Lupus mononeuritis multiplex typically shows axonal rather than demyelinating features. HNPP would show conduction abnormalities at typical compression sites without temporal dispersion.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: K (Miskeyed). Verdict: The keyed answer D (Lewis-Sumner syndrome) is not the best fit for the described symmetric presentation. The stem explicitly states 'symmetric weakness of finger abduction and adduction bilaterally,' which characterizes CIDP (option B), not the asymmetric multifocal pattern of Lewis-Sumner syndrome (MADSAM). Key discriminating clues include: symmetric sensorimotor deficits, demyelinating features with conduction block, elevated CSF protein, and negative anti-ganglioside antibodies—all compatible with CIDP. While Lewis-Sumner syndrome shares demyelinating features, its defining characteristic is asymmetric, multifocal involvement, which is absent here. Alternative options are appropriately excluded: MMNCB is pure motor and antibody-positive; lupus mononeuritis multiplex is axonal; HNPP is hereditary and lacks temporal dispersion. The item is medically accurate in its descriptions but underspecified for distinguishing CIDP from Lewis-Sumner syndrome. Minimal fix: Change 'symmetric' to 'asymmetric, multifocal' involvement in the examination description to align with the keyed answer.\",\"medical_accuracy_score\":  \t\"3\",\"logical_validity\": false,\"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed). Verdict: The keyed answer D (Lewis-Sumner syndrome) is not the best fit for the described symmetric presentation. The stem explicitly states 'symmetric weakness of finger abduction and adduction bilaterally,' which characterizes CIDP (option B), not the asymmetric multifocal pattern of Lewis-Sumner syndrome (MADSAM). Key discriminating clues include: symmetric sensorimotor deficits, demyelinating features with conduction block, elevated CSF protein, and negative anti-ganglioside antibodies—all compatible with CIDP. While Lewis-Sumner syndrome shares demyelinating features, its defining characteristic is asymmetric, multifocal involvement, which is absent here. Alternative options are appropriately excluded: MMNCB is pure motor and antibody-positive; lupus mononeuritis multiplex is axonal; HNPP is hereditary and lacks temporal dispersion. The item is medically accurate in its descriptions but underspecified for distinguishing CIDP from Lewis-Sumner syndrome. Minimal fix: Change 'symmetric' to 'asymmetric, multifocal' involvement in the examination description to align with the keyed answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-002", "question": "A 28-year-old woman at 32 weeks gestation presents with sudden onset severe headache, visual disturbances, and confusion. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 68,000/μL, LDH 890 U/L, AST 245 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. She receives magnesium sulfate and labetalol. Emergent cesarean delivery is performed. Postpartum day 3, despite delivery, her platelet count drops to 42,000/μL, creatinine rises to 2.9 mg/dL, and she develops new neurological symptoms. ADAMTS13 activity returns at 58%. Which additional finding would most strongly support initiating eculizumab therapy?", "options": ["Positive direct antiglobulin test", "Complement factor H mutation on genetic testing", "Elevated soluble fms-like tyrosine kinase-1 levels", "Low C3 with normal C4 levels", "Presence of anti-phospholipid antibodies"], "answer": "B", "answer_index": 1, "explanation": "This presentation of postpartum thrombotic microangiopathy not resolving after delivery with ADAMTS13 >10% suggests complement-mediated TMA (atypical HUS) rather than TTP or HELLP syndrome. Complement factor H mutation confirms complement dysregulation and strongly supports eculizumab (C5 inhibitor) therapy. Low C3 with normal C4 suggests alternative pathway activation but is nonspecific. Elevated sFlt-1 would suggest ongoing preeclampsia-related pathology. Positive DAT would suggest Evans syndrome, and anti-phospholipid antibodies suggest catastrophic APS, both requiring different management.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. Key discriminating clues: postpartum thrombotic microangiopathy with MAHA (schistocytes), thrombocytopenia, renal dysfunction, and ADAMTS13 activity 58% (>10% threshold) effectively rules out TTP; clinical worsening after delivery argues against HELLP syndrome. This pattern strongly suggests complement-mediated atypical HUS. Option B (complement factor H mutation) provides definitive genetic evidence of complement dysregulation, the pathophysiologic basis for eculizumab therapy. Alternative options are correctly excluded: DAT positivity suggests immune hemolysis (Evans syndrome); elevated sFlt-1 indicates preeclampsia/HELLP pathophysiology; low C3/normal C4 is nonspecific for alternative pathway activation; anti-phospholipid antibodies suggest catastrophic APS requiring anticoagulation, not complement blockade. Each distractor points to a distinct alternative diagnosis requiring different management. The item is logically coherent with a single best answer supported by the key. No medical inaccuracies; aligns with current understanding of postpartum TMA differentiation and complement-mediated aHUS management. Minimal fix: None required—item is board-ready as written for clinical use.\",\"medical_accuracy_score\":   \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. Key discriminating clues: postpartum thrombotic microangiopathy with MAHA (schistocytes), thrombocytopenia, renal dysfunction, and ADAMTS13 activity 58% (>10% threshold) effectively rules out TTP; clinical worsening after delivery argues against HELLP syndrome. This pattern strongly suggests complement-mediated atypical HUS. Option B (complement factor H mutation) provides definitive genetic evidence of complement dysregulation, the pathophysiologic basis for eculizumab therapy. Alternative options are correctly excluded: DAT positivity suggests immune hemolysis (Evans syndrome); elevated sFlt-1 indicates preeclampsia/HELLP pathophysiology; low C3/normal C4 is nonspecific for alternative pathway activation; anti-phospholipid antibodies suggest catastrophic APS requiring anticoagulation, not complement blockade. Each distractor points to a distinct alternative diagnosis requiring different management. The item is logically coherent with a single best answer supported by the key. No medical inaccuracies; aligns with current understanding of postpartum TMA differentiation and complement-mediated aHUS management. Minimal fix: None required—item is board-ready as written for clinical use.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-003", "question": "A 52-year-old man with hypertrophic cardiomyopathy and an ICD presents with recurrent appropriate shocks for ventricular tachycardia despite maximum tolerated doses of metoprolol and disopyramide. Echocardiogram shows septal thickness of 22 mm, LVOT gradient of 85 mmHg at rest, and moderate mitral regurgitation with systolic anterior motion. Cardiac MRI demonstrates 18% late gadolinium enhancement predominantly in the septum. Coronary angiography is normal. Which intervention is most likely to reduce his arrhythmia burden?", "options": ["Alcohol septal ablation", "Surgical septal myectomy with mitral valve repair", "Catheter ablation of ventricular tachycardia", "Addition of amiodarone to current regimen", "Cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "In HCM patients with significant LVOT obstruction, extensive LGE (>15%), and recurrent VT, surgical myectomy is preferred over alcohol septal ablation because ASA creates additional scar that may be proarrhythmic. Myectomy reduces obstruction and allows concomitant mitral valve repair for SAM-related MR. The extensive LGE indicates high arrhythmic substrate burden. VT ablation addresses the arrhythmia but not the underlying obstruction driving symptoms. Amiodarone adds toxicity risk without addressing mechanism. Transplant is premature given available surgical options.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: M (Multiple answers defensible), secondary U (Underspecified). The stem asks which intervention is 'most likely to reduce arrhythmia burden' in HCM with severe LVOT obstruction (85 mmHg), extensive LGE (18%), and recurrent VT despite maximal therapy. Key features: high arrhythmic substrate, SAM-related MR. Surgical myectomy (B) addresses obstruction and avoids ASA's theoretical proarrhythmic scar, while catheter VT ablation (C) directly targets documented arrhythmia per guidelines. Amiodarone (D) is also valid. Both B and C are near-equally defensible depending on interpretation—immediate VT suppression versus substrate modification—making the item ambiguous. Medical accuracy: score 3; rationale overstates myectomy's antiarrhythmic superiority and presents ASA's proarrhythmic risk as established fact when evidence is equivocal. Fix: revise stem to ask 'best next step in overall management' or specify substrate modification as the goal.\",\"medical_accuracy_score\":   \"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (Multiple answers defensible), secondary U (Underspecified). The stem asks which intervention is 'most likely to reduce arrhythmia burden' in HCM with severe LVOT obstruction (85 mmHg), extensive LGE (18%), and recurrent VT despite maximal therapy. Key features: high arrhythmic substrate, SAM-related MR. Surgical myectomy (B) addresses obstruction and avoids ASA's theoretical proarrhythmic scar, while catheter VT ablation (C) directly targets documented arrhythmia per guidelines. Amiodarone (D) is also valid. Both B and C are near-equally defensible depending on interpretation—immediate VT suppression versus substrate modification—making the item ambiguous. Medical accuracy: score 3; rationale overstates myectomy's antiarrhythmic superiority and presents ASA's proarrhythmic risk as established fact when evidence is equivocal. Fix: revise stem to ask 'best next step in overall management' or specify substrate modification as the goal.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-004", "question": "A 45-year-old woman with dermatomyositis diagnosed 8 months ago presents with progressive dyspnea. She was initially treated with high-dose prednisone and azathioprine with improvement in proximal muscle weakness. CT chest shows new ground-glass opacities with peripheral consolidation in lower lobes. Pulmonary function tests reveal FVC 58% predicted, DLCO 42% predicted. Bronchoalveolar lavage shows 35% lymphocytes. She tests positive for anti-MDA5 antibodies. Which treatment approach offers the best chance of halting disease progression?", "options": ["Increase prednisone and add mycophenolate mofetil", "Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide", "Rituximab with continued azathioprine", "Nintedanib with continued current immunosuppression", "Plasma exchange followed by IVIG maintenance"], "answer": "B", "answer_index": 1, "explanation": "Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease carries high mortality and requires aggressive upfront combination immunosuppression. Japanese and international experience supports triple therapy with high-dose corticosteroids, a calcineurin inhibitor (tacrolimus or cyclosporine), and cyclophosphamide as the most effective approach for halting progression. Single-agent additions or rituximab have shown inferior outcomes in this specific antibody subset. Nintedanib is antifibrotic, not immunosuppressive. Plasma exchange lacks evidence in this context.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Keyed answer is correct and uniquely defensible. Critical stem discriminators—anti-MDA5 positivity, progressive dyspnea despite high-dose prednisone/azathioprine, severe PFT reduction (FVC 58%, DLCO 42%), and new ground-glass opacities—establish treatment-refractory, anti-MDA5–associated rapidly progressive ILD with >50% mortality. Current consensus and emerging data (Japanese cohorts, international registries) support aggressive upfront triple immunosuppression (high-dose glucocorticoids + calcineurin inhibitor + cyclophosphamide) as the most effective strategy to halt progression, making option B unequivocally best. Alternative A (steroid increase + MMF) is insufficiently aggressive; C (rituximab) lacks robust first-line evidence in this subset; D (nintedanib) targets fibrosis, not active inflammation; E (plasma exchange/IVIG) is unsupported. No internal contradictions exist, and options permit clear discrimination. Medical accuracy aligns with 2020 ACR/EULAR ILD guidance and recent anti-MDA5 literature. No revisions required.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Keyed answer is correct and uniquely defensible. Critical stem discriminators—anti-MDA5 positivity, progressive dyspnea despite high-dose prednisone/azathioprine, severe PFT reduction (FVC 58%, DLCO 42%), and new ground-glass opacities—establish treatment-refractory, anti-MDA5–associated rapidly progressive ILD with >50% mortality. Current consensus and emerging data (Japanese cohorts, international registries) support aggressive upfront triple immunosuppression (high-dose glucocorticoids + calcineurin inhibitor + cyclophosphamide) as the most effective strategy to halt progression, making option B unequivocally best. Alternative A (steroid increase + MMF) is insufficiently aggressive; C (rituximab) lacks robust first-line evidence in this subset; D (nintedanib) targets fibrosis, not active inflammation; E (plasma exchange/IVIG) is unsupported. No internal contradictions exist, and options permit clear discrimination. Medical accuracy aligns with 2020 ACR/EULAR ILD guidance and recent anti-MDA5 literature. No revisions required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-005", "question": "A 38-year-old man from Cambodia presents with 3 weeks of fever, headache, and altered mental status. CSF analysis shows opening pressure 32 cm H2O, WBC 180/μL (90% lymphocytes), protein 120 mg/dL, glucose 28 mg/dL (serum 110 mg/dL). India ink preparation shows encapsulated yeast. Cryptococcal antigen titer is 1:2048 in CSF. HIV testing is positive with CD4 count of 35 cells/μL. He is started on liposomal amphotericin B and flucytosine with daily therapeutic lumbar punctures. On day 10, repeat lumbar puncture shows opening pressure 38 cm H2O, CSF WBC 420/μL (85% lymphocytes), protein 180 mg/dL, and cryptococcal antigen titer 1:1024. He has worsening headache and new sixth nerve palsy. What is the most appropriate next step?", "options": ["Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome", "Switch to high-dose fluconazole for amphotericin resistance", "Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure", "Continue current antifungal therapy with more aggressive CSF drainage", "Initiate antiretroviral therapy immediately to improve immune function"], "answer": "D", "answer_index": 3, "explanation": "The rising CSF pleocytosis with persistent elevated opening pressure despite treatment represents ongoing cryptococcal meningitis with inadequate pressure management rather than treatment failure or IRIS (patient not yet on ART). The antigen titer is decreasing appropriately. Management requires more aggressive CSF drainage-either more frequent LPs or temporary lumbar drain placement. Corticosteroids are contraindicated in cryptococcal meningitis (increased mortality in COAT trial). VPS is reserved for truly refractory cases after optimizing medical management. Early ART initiation increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V. Verdict: Correct best answer. Key stem clues: Advanced HIV (CD4 35) with cryptococcal meningitis on appropriate induction therapy (liposomal amphotericin B + flucytosine) and daily therapeutic LPs; at day 10, CSF cryptococcal antigen appropriately decreases (1:2048→1:1024) while opening pressure rises (32→38 cm H2O) with worsening headache and new sixth nerve palsy, indicating inadequately controlled intracranial pressure rather than treatment failure. Main logical issue: None; the vignette provides clear discrimination: antifungal efficacy is demonstrated by falling antigen, while clinical deterioration stems from persistent ICP, mandating more aggressive drainage. Alternative options are appropriately excluded—steroids are contraindicated (COAT trial mortality data), early ART increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy, fluconazole switch is unwarranted for induction, and VP shunt is reserved for truly refractory cases after maximal medical management. Main medical accuracy issue: None; item accurately reflects current IDSA guidelines and landmark trial evidence. Minimal fix: None required; item is board-examination ready with precise, guideline-concordant details that uniquely support option D.\",\n\"medical_accuracy_score\":    \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: Advanced HIV (CD4 35) with cryptococcal meningitis on appropriate induction therapy (liposomal amphotericin B + flucytosine) and daily therapeutic LPs; at day 10, CSF cryptococcal antigen appropriately decreases (1:2048→1:1024) while opening pressure rises (32→38 cm H2O) with worsening headache and new sixth nerve palsy, indicating inadequately controlled intracranial pressure rather than treatment failure. Main logical issue: None; the vignette provides clear discrimination: antifungal efficacy is demonstrated by falling antigen, while clinical deterioration stems from persistent ICP, mandating more aggressive drainage. Alternative options are appropriately excluded—steroids are contraindicated (COAT trial mortality data), early ART increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy, fluconazole switch is unwarranted for induction, and VP shunt is reserved for truly refractory cases after maximal medical management. Main medical accuracy issue: None; item accurately reflects current IDSA guidelines and landmark trial evidence. Minimal fix: None required; item is board-examination ready with precise, guideline-concordant details that uniquely support option D.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-006", "question": "A 67-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab develops progressive cognitive decline over 4 months. MRI brain shows multifocal white matter lesions without enhancement or mass effect. CSF shows 8 WBCs (all lymphocytes), protein 62 mg/dL, and negative routine cultures. JC virus PCR in CSF is positive with 850 copies/mL. Adalimumab is discontinued. Three weeks later, she develops new right hemiparesis and worsening confusion. Repeat MRI shows enlargement of lesions with new peripheral enhancement and edema. CSF now shows 45 WBCs (predominantly lymphocytes). What is the most appropriate management?", "options": ["Restart adalimumab to suppress destructive inflammation", "Initiate high-dose corticosteroids", "Begin cidofovir and cytarabine combination therapy", "Administer pembrolizumab to enhance JC virus clearance", "Perform brain biopsy to exclude CNS lymphoma"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed immune reconstitution inflammatory syndrome (IRIS) following discontinuation of immunosuppression in the setting of PML. The new enhancement, edema, and increased CSF pleocytosis after stopping adalimumab are classic for PML-IRIS. High-dose corticosteroids are indicated to reduce the inflammatory response that, while representing immune recovery, can cause significant neurological damage. Restarting immunosuppression would be counterproductive. Cidofovir/cytarabine lack efficacy in PML. Pembrolizumab is used in refractory PML without immune reconstitution, not IRIS. Biopsy is unnecessary given confirmed JC virus and classic IRIS presentation.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The vignette depicts PML-IRIS following adalimumab discontinuation. Key discriminating findings: rheumatoid arthritis patient on dual immunosuppression (methotrexate, adalimumab), 4-month progressive cognitive decline, MRI showing non-enhancing white matter lesions, CSF JC virus PCR positivity (850 copies/mL), and definitive IRIS features emerging 3 weeks after stopping adalimumab—clinical deterioration, new lesion enhancement/edema, and CSF pleocytosis increase to 45 lymphocytes. The keyed answer (high-dose corticosteroids) is the standard-of-care treatment to control destructive immune-mediated inflammation while maintaining antiviral immunity. Each distractor is appropriately flawed: restarting adalimumab (A) would suppress beneficial immune recovery; cidofovir/cytarabine (C) have no proven efficacy in PML; pembrolizumab (D) is experimental for PML without immune reconstitution, not IRIS; brain biopsy (E) is unnecessary with confirmed JC virus and classic IRIS radiology. The item has no logical contradictions, allows clear discrimination, and the key aligns with current neurology and infectious disease consensus. Medical accuracy is gold-standard. Minimal fix: none required.\",\"medical_accuracy_score\":    \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The vignette depicts PML-IRIS following adalimumab discontinuation. Key discriminating findings: rheumatoid arthritis patient on dual immunosuppression (methotrexate, adalimumab), 4-month progressive cognitive decline, MRI showing non-enhancing white matter lesions, CSF JC virus PCR positivity (850 copies/mL), and definitive IRIS features emerging 3 weeks after stopping adalimumab—clinical deterioration, new lesion enhancement/edema, and CSF pleocytosis increase to 45 lymphocytes. The keyed answer (high-dose corticosteroids) is the standard-of-care treatment to control destructive immune-mediated inflammation while maintaining antiviral immunity. Each distractor is appropriately flawed: restarting adalimumab (A) would suppress beneficial immune recovery; cidofovir/cytarabine (C) have no proven efficacy in PML; pembrolizumab (D) is experimental for PML without immune reconstitution, not IRIS; brain biopsy (E) is unnecessary with confirmed JC virus and classic IRIS radiology. The item has no logical contradictions, allows clear discrimination, and the key aligns with current neurology and infectious disease consensus. Medical accuracy is gold-standard. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. Stem provides classic Behçet features (recurrent oral/genital ulcers, bilateral anterior uveitis) reinforced by HLA-B51 positivity; negative pathergy appropriately does not negate diagnosis given its limited sensitivity. Acute CRAO with box-carring indicates inflammatory vasculitic occlusion requiring systemic therapy. The query's emphasis on preventing contralateral involvement correctly frames management as aggressive immunosuppression rather than ocular emergency maneuvers. Keyed answer D reflects current standard-of-care: high-dose corticosteroids plus anti-TNF therapy (infliximab/adalimumab) for sight-threatening ocular Behçet per EULAR guidelines. Distractors are well-constructed: A and C insufficiently aggressive for this severity; B less optimal than combination for acute control; E targets embolic pathophysiology, irrelevant to vasculitic occlusion. No internal contradictions or critical missing details. Item permits clear discrimination and tests appropriate therapeutic escalation. Medical content is accurate, contemporary, and board-relevant. Minimal fix: None required.\",\"medical_accuracy_score\":    \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Stem provides classic Behçet features (recurrent oral/genital ulcers, bilateral anterior uveitis) reinforced by HLA-B51 positivity; negative pathergy appropriately does not negate diagnosis given its limited sensitivity. Acute CRAO with box-carring indicates inflammatory vasculitic occlusion requiring systemic therapy. The query's emphasis on preventing contralateral involvement correctly frames management as aggressive immunosuppression rather than ocular emergency maneuvers. Keyed answer D reflects current standard-of-care: high-dose corticosteroids plus anti-TNF therapy (infliximab/adalimumab) for sight-threatening ocular Behçet per EULAR guidelines. Distractors are well-constructed: A and C insufficiently aggressive for this severity; B less optimal than combination for acute control; E targets embolic pathophysiology, irrelevant to vasculitic occlusion. No internal contradictions or critical missing details. Item permits clear discrimination and tests appropriate therapeutic escalation. Medical content is accurate, contemporary, and board-relevant. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-008", "question": "A 41-year-old man with no significant medical history presents with 6 weeks of progressive bilateral lower extremity weakness and paresthesias. He reports a diarrheal illness 8 weeks ago. Examination shows 3/5 strength in hip flexors, 4/5 in knee extensors, 4-/5 in ankle dorsiflexors bilaterally, absent deep tendon reflexes, and decreased vibration sense to the knees. Nerve conduction studies show reduced CMAP amplitudes with normal conduction velocities and no conduction block. Needle EMG shows active denervation in distal leg muscles. CSF protein is 95 mg/dL with 1 WBC. Anti-GM1 IgG antibodies are strongly positive. Despite 5 days of IVIG, he continues to worsen with new respiratory compromise requiring intubation. What is the next best step in management?", "options": ["Repeat IVIG course immediately", "Initiate plasma exchange", "Add high-dose intravenous methylprednisolone", "Begin eculizumab therapy", "Administer second IVIG course after 4-week interval"], "answer": "B", "answer_index": 1, "explanation": "This patient has acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, evidenced by pure motor axonal pattern on NCS, anti-GM1 antibodies, and preceding Campylobacter-like illness. When patients fail to respond to initial IVIG and continue deteriorating, plasma exchange is the appropriate next step as it works through a different mechanism (antibody removal vs. immunomodulation). The treatments are not synergistic when given together but can be used sequentially. Corticosteroids are ineffective in GBS. Eculizumab has shown promise in refractory cases but is not yet standard of care. Waiting 4 weeks for repeat IVIG is inappropriate in a deteriorating patient.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. This item tests rescue therapy for treatment-refractory AMAN variant GBS. Key discriminating clues include: preceding diarrheal illness, pure motor axonal pattern on NCS (reduced CMAP amplitudes, normal velocities), strongly positive anti-GM1 IgG antibodies, albuminocytologic dissociation in CSF, and clinical deterioration with respiratory failure despite IVIG. These features collectively point to AMAN, where plasma exchange is the established next step after IVIG failure per AAN/ASFA guidelines. Alternative options are appropriately inferior: immediate repeat IVIG lacks evidence and is less effective than PE; corticosteroids are ineffective in GBS; eculizumab remains experimental; waiting 4 weeks is unsafe in a deteriorating patient. The 6-week progression is atypical for GBS (usually <4 weeks to nadir), creating minor clinical realism tension, but does not prevent selection of a unique best answer or undermine the core management principle. No medical inaccuracies are present. Minimal fix: Revise timeline to '3 weeks of progressive weakness' to align with classic GBS diagnostic criteria while preserving the teaching point.\",\"medical_accuracy_score\":   \t\"4\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. This item tests rescue therapy for treatment-refractory AMAN variant GBS. Key discriminating clues include: preceding diarrheal illness, pure motor axonal pattern on NCS (reduced CMAP amplitudes, normal velocities), strongly positive anti-GM1 IgG antibodies, albuminocytologic dissociation in CSF, and clinical deterioration with respiratory failure despite IVIG. These features collectively point to AMAN, where plasma exchange is the established next step after IVIG failure per AAN/ASFA guidelines. Alternative options are appropriately inferior: immediate repeat IVIG lacks evidence and is less effective than PE; corticosteroids are ineffective in GBS; eculizumab remains experimental; waiting 4 weeks is unsafe in a deteriorating patient. The 6-week progression is atypical for GBS (usually <4 weeks to nadir), creating minor clinical realism tension, but does not prevent selection of a unique best answer or undermine the core management principle. No medical inaccuracies are present. Minimal fix: Revise timeline to '3 weeks of progressive weakness' to align with classic GBS diagnostic criteria while preserving the teaching point.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-009", "question": "A 55-year-old woman with mechanical mitral valve replacement on warfarin presents with acute onset aphasia and right hemiplegia. Symptoms began 90 minutes ago. CT head shows no hemorrhage. CT angiography reveals left M1 occlusion. INR is 2.8. CT perfusion shows large penumbra with small core infarct (ASPECTS 8). Blood pressure is 165/95 mmHg. What is the most appropriate next step?", "options": ["Administer IV alteplase followed by endovascular thrombectomy", "Proceed directly to endovascular thrombectomy without IV thrombolysis", "Reverse anticoagulation with 4-factor PCC then administer IV alteplase", "Administer idarucizumab followed by IV alteplase", "Medical management only with blood pressure optimization"], "answer": "B", "answer_index": 1, "explanation": "In patients with acute ischemic stroke on therapeutic anticoagulation (INR >1.7), IV thrombolysis is contraindicated due to bleeding risk. However, mechanical thrombectomy is not contraindicated and should be pursued emergently in patients with large vessel occlusion and favorable perfusion imaging (large penumbra, small core). Reversing anticoagulation to give tPA adds delay and the combination increases bleeding risk. Idarucizumab reverses dabigatran, not warfarin. Medical management alone would result in completed large territory infarction given the M1 occlusion. Direct thrombectomy offers the best risk-benefit profile.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. Key stem clues driving the decision: therapeutic anticoagulation with INR 2.8 (exceeds the >1.7 threshold contraindicating IV thrombolysis), left M1 occlusion with favorable perfusion imaging (large penumbra, ASPECTS 8) indicating eligibility for mechanical thrombectomy, and symptom onset within 90 minutes. The item logically eliminates IV alteplase (Option A) based on guideline-defined contraindication, idarucizumab (Option D) due to mechanism mismatch (reverses dabigatran, not warfarin), and medical management alone (Option E) given the large vessel occlusion with salvageable tissue. Option C is suboptimal because reversing anticoagulation adds critical delay without clear benefit. Option B emerges as uniquely defensible: direct endovascular thrombectomy is indicated, safe, and guideline-concordant for anticoagulated patients with large vessel occlusion. No logical contradictions or underspecification. Medical accuracy is gold-standard: aligns with AHA/ASA stroke guidelines regarding thrombolysis contraindications and thrombectomy indications. Minimal fix: none required; item is board-ready.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. Key stem clues driving the decision: therapeutic anticoagulation with INR 2.8 (exceeds the >1.7 threshold contraindicating IV thrombolysis), left M1 occlusion with favorable perfusion imaging (large penumbra, ASPECTS 8) indicating eligibility for mechanical thrombectomy, and symptom onset within 90 minutes. The item logically eliminates IV alteplase (Option A) based on guideline-defined contraindication, idarucizumab (Option D) due to mechanism mismatch (reverses dabigatran, not warfarin), and medical management alone (Option E) given the large vessel occlusion with salvageable tissue. Option C is suboptimal because reversing anticoagulation adds critical delay without clear benefit. Option B emerges as uniquely defensible: direct endovascular thrombectomy is indicated, safe, and guideline-concordant for anticoagulated patients with large vessel occlusion. No logical contradictions or underspecification. Medical accuracy is gold-standard: aligns with AHA/ASA stroke guidelines regarding thrombolysis contraindications and thrombectomy indications. Minimal fix: none required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-010", "question": "A 33-year-old woman with no prior cardiac history presents with progressive exertional dyspnea over 3 months. She delivered her third child 5 months ago. Echocardiogram shows left ventricular ejection fraction of 25%, LV end-diastolic diameter of 62 mm, moderate functional mitral regurgitation, and no thrombus. BNP is 1,850 pg/mL. She is started on guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Genetic testing reveals a truncating variant in the TTN gene. At 6-month follow-up, LVEF has improved to 40% but remains below normal. Which factor most strongly predicts her likelihood of complete LV recovery?", "options": ["Absence of late gadolinium enhancement on cardiac MRI", "Normalization of BNP levels", "Presence of the TTN truncating variant", "Baseline LVEF above 30%", "Multiparity status"], "answer": "A", "answer_index": 0, "explanation": "In peripartum cardiomyopathy, the absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest predictor of complete LV recovery, indicating absence of irreversible myocardial fibrosis. TTN truncating variants are actually associated with incomplete recovery and persistent LV dysfunction in PPCM, making option C incorrect. While BNP normalization and higher baseline LVEF are favorable, they are less predictive than LGE status. Multiparity is a risk factor for developing PPCM but does not predict recovery. LGE represents scar that cannot recover regardless of optimal medical therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V. Verdict: Correct best answer. Key stem clues establishing PPCM context include: 33-year-old woman, 5 months postpartum, LVEF 25% with dilation, functional MR, elevated BNP, and partial recovery to 40% on optimal GDMT (ARNI, beta-blocker, MRA, SGLT2i). The TTN truncating variant is explicitly mentioned, which is crucial as it makes option C incorrect (TTN variants predict incomplete recovery, not recovery). The question asks which factor most strongly predicts complete LV recovery. Absence of LGE on cardiac MRI is indeed the strongest predictor, as LGE indicates irreversible fibrosis that precludes full recovery regardless of therapy. Alternative options are inferior: BNP normalization is favorable but less predictive; baseline LVEF >30% is favorable but less predictive than tissue characterization; multiparity is a risk factor for developing PPCM, not for recovery. No logical flaws: a single best answer exists, the key matches it, and options are discriminating. Medical accuracy is excellent and current with 2020s PPCM literature. No contradictions or underspecification. The vignette doesn't need to state LGE status because the question tests knowledge of predictive factors, not interpretation of existing results. Minimal fix: none required.\",\n\"medical_accuracy_score\":   \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Key stem clues establishing PPCM context include: 33-year-old woman, 5 months postpartum, LVEF 25% with dilation, functional MR, elevated BNP, and partial recovery to 40% on optimal GDMT (ARNI, beta-blocker, MRA, SGLT2i). The TTN truncating variant is explicitly mentioned, which is crucial as it makes option C incorrect (TTN variants predict incomplete recovery, not recovery). The question asks which factor most strongly predicts complete LV recovery. Absence of LGE on cardiac MRI is indeed the strongest predictor, as LGE indicates irreversible fibrosis that precludes full recovery regardless of therapy. Alternative options are inferior: BNP normalization is favorable but less predictive; baseline LVEF >30% is favorable but less predictive than tissue characterization; multiparity is a risk factor for developing PPCM, not for recovery. No logical flaws: a single best answer exists, the key matches it, and options are discriminating. Medical accuracy is excellent and current with 2020s PPCM literature. No contradictions or underspecification. The vignette doesn't need to state LGE status because the question tests knowledge of predictive factors, not interpretation of existing results. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]